The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease
Open accessAbstract
Purpose: Pediatric Oncology Group (POG) studies 9426 and 9425 evaluated dexrazoxane (DRZ) as a cardiopulmonary protectant during treatment for Hodgkin's disease (HD). We evaluated incidence and risk factors of acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and second malignant neoplasms (SMNs). Patients and Methods: Treatment for low- and high-risk HD with doxorubicin, bleomycin, vincristine, and etoposide (ABVE) or dose-intensified ABVE with prednisone and cyclophosphamide (ABVE-PC), respectively, was followed by low-dose radiation. The number of chemotherapy cycles was determined by rapidity of the initial response. Patients were assigned randomly to receive DRZ (n = 239) or no DRZ (n = 239) concomitantly with chemotherapy to evaluate its potential to decrease adverse cardiopulmonary outcomes. Results: Ten patients developed SMN. Six of eight patients developed AML/MDS, and both solid tumors (osteosarcoma and papillary thyroid carcinoma) occurred in recipients of DRZ. Eight patients with SMN were first events. With median 58 months' follow-up, 4-year cumulative incidence rate (CIR) for AML/MDS was 2.55% ± 1.0% with DRZ versus 0.85% ± 0.6% in the non-DRZ group (P = .160). For any SMN, the CIR for DRZ was 3.43% ± 1.2% versus CIR for non-DRZ of 0.85% ± 0.6% (P = .060). Among patients receiving DRZ, the standardized incidence rate (SIR) for AML/MDS was 613.6 compared with 202.4 for those not receiving DRZ (P = .0990). The SIR for all SMN was 41.86 with DRZ versus 10.08 without DRZ (P = .0231). Conclusion: DRZ is a topoisomerase II inhibitor with a mechanism distinct from etoposide and doxorubicin. Adding DRZ to ABVE and ABVE-PC may have increased the incidence of SMN and AML/MDS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
McCullagh, P., & Nelder, J. A. (1989) · doi:10.1007/978-1-4899-3242-6 · Cited by 16,836
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Statistical Methods in Cancer Research. Volume II – The Design and Analysis of Cohort Studies
Juul, S. (1989) · Scandinavian Journal of Social Medicine · doi:10.1177/140349488901700214 · Cited by 3,592
Balboni, T. A., Vanderwerker, L. C., Block, S. D., Paulk, M. E., Lathan, C. S., Peteet, J. R., & Prigerson, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9046 · Cited by 959
Breast Cancer and Other Second Neoplasms after Childhood Hodgkin's Disease
Bhatia, S., Robison, L. L., Oberlin, O., Greenberg, M., Bunin, G., Fossati-Bellani, F., & Meadows, A. T. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341201 · Cited by 905
Neglia, J. P., Friedman, D. L., Yasui, Y., Mertens, A. C., Hammond, S., Stovall, M., Donaldson, S. S., Meadows, A. T., & Robison, L. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.618 · Cited by 741
Self-citationBreast Cancer Following Radiotherapy and Chemotherapy Among Young Women With Hodgkin Disease
Travis, L. B., Hill, D. A., Dores, G. M., Gospodarowicz, M., van Leeuwen, F. E., Holowaty, E., Glimelius, B., Andersson, M., Wiklund, T., Lynch, C. F., et al. (2003) · JAMA · doi:10.1001/jama.290.4.465 · Cited by 666
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Leukemia Following Hodgkin's Disease
Kaldor, J. M., Day, N. E., Clarke, E. A., Van Leeuwen, F. E., Henry-Amar, M., Fiorentino, M. V., Bell, J., Pedersen, D., Band, P., Assouline, D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199001043220102 · Cited by 485
Cited by
Zamorano, J. L., Lancellotti, P., Rodriguez Muñoz, D., Aboyans, V., Asteggiano, R., Galderisi, M., Habib, G., Lenihan, D. J., Lip, G. Y. H., Lyon, A. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw211 · Cited by 2,544
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2012.03.006 · Cited by 1,414
Prevention of Anthracycline-Induced Cardiotoxicity
Vejpongsa, P., & Yeh, E. T. H. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1167 · Cited by 671
Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity
Tadokoro, T., Ikeda, M., Ide, T., Deguchi, H., Ikeda, S., Okabe, K., Ishikita, A., Matsushima, S., Koumura, T., Yamada, K.-I., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.132747 · Cited by 655
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Self-citation
Metadata
- Authors
- Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-02-10
- Volume
- 25
- Issue
- 5
- Pages
- 493-500
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2112357840
- Cited by
- 493
- References
- 34
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease. https://app.cochat.ai/papers/10.1200/jco.2005.02.3879
- The paper
- Tebbi, C. K., London, W. B., Friedman, D., Villaluna, D., De Alarcon, P. A., Constine, L. S., Mendenhall, N. P., Sposto, R., Chauvenet, A., & Schwartz, C. L. (2007). Dexrazoxane-Associated Risk for Acute Myeloid Leukemia/Myelodysplastic Syndrome and Other Secondary Malignancies in Pediatric Hodgkin's Disease. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.02.3879
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.